# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-046926
Filing Date
2020-04-15
Accepted
2020-04-15 16:30:15
Documents
6
Period of Report
2020-06-07
Effectiveness Date
2020-04-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2015338-1_def14a.htm | DEF 14A | 700539
2 | GRAPHIC | lg_protalix.jpg | GRAPHIC | 37587
3 | GRAPHIC | sg_drorbashan.jpg | GRAPHIC | 126889
4 | GRAPHIC | sg_eyalrubin-bw.jpg | GRAPHIC | 45860
5 | GRAPHIC | tm2015338d1-pc1.jpg | GRAPHIC | 471316
6 | GRAPHIC | tm2015338d1-pc2.jpg | GRAPHIC | 693696
| Complete submission text file | 0001104659-20-046926.txt |  | 2591871

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 20794035
SIC: 2836 Biological Products, (No Diagnostic Substances)